Trial ID 20412 | Maryland Oncology Hematology Trial ID 20412 – Maryland Oncology Hematology

Trial ID 20412

Trial Information - Phase III

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432)

Disease Specifics: NSCLC

Protocol ID: J2G-MC-JZJX

Sponsor: ELI LILLY

Status: STAR Trial

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lung

Status

STAR Trial

Sponsor

ELI LILLY

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology